Mycophenolate Mofetil in Membranous Nephropathy
Patients with idiopathic membranous nephropathy and renal insufficiency are at risk for end-stage renal disease (ESRD). Treatment with cyclophosphamide is currently used as a treatment modality. Mycophenolate mofetil is a new immunosuppressive agent with fewer side effects.
In this pilot study patients with membranous nephropathy and renal failure will be treated with mycophenolate mofetil and prednisone. The outcome will be compared with historical controls treated with a similar regimen containing cyclophosphamide.
|Glomerulonephritis, Membranous||Drug: mycophenolate mofetil orally 1000 mg twice a day (BID) Drug: prednisone 0,5 mg/kg orally on alternate days Drug: intravenous (i.v.) methylprednisolone 1000 mg, total 9||Phase 2 Phase 3|
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Treatment of Patients With Membranous Nephropathy and Renal Insufficiency With Mycophenolate Mofetil and Prednisone: a Pilot Study|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00135967
|Department of Nephrology Radboud University Nijmegen Medical Centre|
|Nijmegen, Netherlands, 6500 HB|
|Principal Investigator:||Jack F Wetzels, MD||Radboud University|